A neural circuits platform to accelerate and de-risk preclinical neuropsychiatric drug development

Time: 10:35 am
day: Day Two


• The need for improved in-vivo, in-brain pharmacodynamic readouts for
preclinical therapeutic development
• The Inscopix neural circuits platform for circuit-based
pharmacodynamics and efficacy assessments
• Case study: striatal circuit signatures corresponding to optimal
antipsychotic effect and clinical performance